• Optimizing Calcium Phosphate Transfection

  2026-10-02

  A 2026 study optimized calcium phosphate transfection in HEK 293T cells by examining plasmid DNA dose together with reaction volume rather than treating DNA quantity as an isolated variable. Its central practical finding is that 80 μg of plasmid DNA in 1 mL of reaction mixture, at 2–3 × 10⁵ cells/mL, produced the most effective condition reported in the study.

• FerroOrange and the Next Frontier in Iron Biology

  2026-10-01

  A translational roadmap for using FerroOrange to connect intracellular Fe²⁺ dynamics with PM2.5-driven macrophage ferroptosis, asthma biology, and more rigorous live-cell validation.

• GS-441524: Applied Antiviral Research Workflows

  2026-10-01

  Build more reproducible GS-441524 antiviral research workflows by combining controlled DMSO preparation, cell-based testing, and LC–MS/MS metabolite tracking. This guide separates parent-compound assays from GS-441524 prodrug conversion studies so researchers can select the right matrix, sampling plan, and troubleshooting strategy.

• Sodium Oxamate: From Lactate to Radiosensitivity

  2026-09-30

  Sodium Oxamate offers translational researchers a practical way to test whether LDH-A-dependent lactate production is causally linked to DNA repair and radioresistance. This article connects metabolic flux, MRE11 lactylation, and triple-negative breast cancer while outlining a rigorous validation strategy that avoids overstating what a metabolic inhibitor can prove.

• IL-7, Human Recombinant: Biology and Workflow

  2026-09-30

  IL-7, human recombinant is a research cytokine for investigating IL-7 receptor signaling, lymphocyte survival, and immune-cell culture. The P1024 product identity does not establish a validated concentration, formulation, endotoxin level, or bioactivity specification, so experimental performance should be confirmed with an assay.

• KU-55933: ATM Kinase Inhibitor Workflows

  2026-09-29

  Build reproducible ATM perturbation experiments with KU-55933, from DMSO stock preparation and phospho-Akt monitoring to cell-cycle, viability, and metabolism readouts. The workflow also shows how ATM inhibition can be used as a controlled mechanistic probe alongside the nuclear cGAS–TRIM41–ORF2p findings reported in recent genome-integrity research.

• EZ Cap™ ER-EGFP Probe mRNA for Imaging

  2026-09-29

  Explore how EZ Cap™ ER-EGFP Probe mRNA (m1Ψ) can support live-cell endoplasmic reticulum labeling and quantitative organelle-proximity analysis. This guide connects transient mRNA expression with a practical super-resolution workflow while clarifying segmentation, resolution, and interpretation limits.

• Pretomanid Targets Both Terminal Oxidases in TB

  2026-09-28

  The reference study shows that pretomanid, also known as PA-824, inhibits both cytochrome bcc:aa3 and cytochrome bd terminal oxidases in Mycobacterium tuberculosis. This dual respiratory effect explains its synergy with telacebec and supports rational combinations that retain bactericidal activity against replicating and antibiotic-tolerant non-replicating bacilli.

• Ziprasidone Targets GOT1 in Pancreatic Cancer

  2026-09-28

  A 2022 study identified ziprasidone as a non-competitive GOT1 inhibitor and linked its inhibition of this enzyme to disrupted glutamine metabolism, redox imbalance, and reduced pancreatic cancer cell growth. The findings support further investigation of GOT1-directed strategies but do not establish clinical efficacy or show that the drug’s established receptor pharmacology explains its antitumor effects.

• Pentoxifylline: PDE Inhibition and Research Uses

  2026-09-27

  Pentoxifylline is a phosphodiesterase inhibitor studied for cAMP-linked immune effects and laboratory sperm motility activation. In-vitro findings depend on concentration, exposure time, and sample type; improved motility alone does not establish improved assisted-reproduction outcomes.

• Doxorubicin: Modeling Tumor Kill and Cardiac Risk

  2026-09-26

  Doxorubicin (Adriamycin) is more than a DNA-damaging cancer model: its tumor activity and cardiac liability can be studied together. This article examines a recent cardioprotection study and shows how its findings can inform paired tumor–cardiac assay design.

• EZ Cap Cy5 Firefly Luciferase mRNA for Delivery

  2026-09-25

  Track labeled mRNA uptake with Cy5, then measure functional protein expression with firefly luciferase in the same experimental program. This dual-readout reporter helps distinguish delivery from translation when optimizing transfection reagents and lipid formulations.

• Caspofungin Workflows for Candida Research

  2026-09-25

  Use Caspofungin as a β-glucan-pathway probe, susceptibility comparator, and benchmark in delayed-treatment Candida studies. A practical workflow connects stock handling and broth microdilution with the key design lessons from a murine C. auris study—without treating preclinical results as a universal prediction of isolate response.

• Adefovir Pharmacokinetics in an OAT1 Cocktail

  2026-09-24

  A population pharmacokinetic reanalysis of 24 healthy volunteers found that co-administration in a transporter cocktail altered apparent adefovir bioavailability and absorption rate, but not renal elimination. The findings support renal clearance as a practical OAT1 phenotyping measure at the tested doses, while emphasizing that the observed interaction likely arose before or during systemic appearance of adefovir.

• DNase I (RNase-free) for RNA QC

  2026-09-24

  Use ribonuclease-free DNase I to remove residual DNA from RNA extraction and in vitro transcription samples before reverse-transcription assays. Paired with suitable controls and cleanup, this step helps distinguish DNA carryover from genuine RNA quality signals—an important consideration when assessing long self-amplifying RNA by ddPCR.

8460 records 1/564 page Next 12345 下5页 Last page